riamilovir and Orthomyxoviridae-Infections

riamilovir has been researched along with Orthomyxoviridae-Infections* in 2 studies

Other Studies

2 other study(ies) available for riamilovir and Orthomyxoviridae-Infections

Article	Year
Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5 Influenza viruses of types A and B cause periodic pandemics in the human population. The antiviral drugs approved to combat influenza virus infections are currently limited. We have investigated an effective novel inhibitor of human influenza A and B viruses, triazavirine [2-methylthio-6-nitro-1,2,4-triazolo[5,1-c]-1,2,4-triazine-7(4I)-one] (TZV). TZV suppressed the replication of influenza virus in cell culture and in chicken chorioallantoic membranes, and it protected mice from death caused by type A and B influenza viruses. TZV was also effective against a rimantadine-resistant influenza virus strain and against avian influenza A virus H5N1 strains. The pharmacokinetic parameters and bioavailability of TZV were calculated after the administration of TZV to rabbits. The TZV metabolite AMTZV [2-methylthio-6-amino-1,2,4-triazolo[5,1-s]-1,2,4-triazin(e)-7(4I)-one] was discovered in IAK 293T and Huh7 cell cultures, a liver homogenate, and rabbit blood after intragastric administration of TZV. AMTZV was nontoxic and inactive as an inhibitor of influenza virus in cell culture. Most likely, this metabolite is a product of TZV elimination. Topics: Animals; Antiviral Agents; Azoles; Disease Models, Animal; Dogs; Drug Design; Hepatocytes; Humans; Influenza A virus; Influenza B virus; Injections, Intravenous; Kidney; Mice; Mice, Inbred CBA; Orthomyxoviridae Infections; Rabbits; Stomach; Triazines; Triazoles; Virus Replication	2010
[Triazavirin prophylactic efficacy against influenza virus A (H5N1)]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2010, Volume: 55, Issue:9-10 The experimental study of the prophylactic efficacy of Triazaverin against the experimental form of the influenza virus A (H5N1) on albino mice intranasally infected with the influenza virus A/Chicken/Kurgan/Russia/02/05 vs. the reference drugs Tamiflu, Remantadin and Arbidol showed that in doses of 1 to 100 mg/kg it was efficient in the animal protection from death. The drug was also efficient in the urgent prophylaxis. Triazaverin effectively inhibited the influenza A virus multiplication in the lungs of the albino mice. Topics: Administration, Oral; Animals; Antiviral Agents; Azoles; Influenza A Virus, H5N1 Subtype; Lung; Mice; Orthomyxoviridae Infections; Russia; Triazines; Triazoles; Virus Replication	2010

Article

Year

Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.

Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5

Influenza viruses of types A and B cause periodic pandemics in the human population. The antiviral drugs approved to combat influenza virus infections are currently limited. We have investigated an effective novel inhibitor of human influenza A and B viruses, triazavirine [2-methylthio-6-nitro-1,2,4-triazolo[5,1-c]-1,2,4-triazine-7(4I)-one] (TZV). TZV suppressed the replication of influenza virus in cell culture and in chicken chorioallantoic membranes, and it protected mice from death caused by type A and B influenza viruses. TZV was also effective against a rimantadine-resistant influenza virus strain and against avian influenza A virus H5N1 strains. The pharmacokinetic parameters and bioavailability of TZV were calculated after the administration of TZV to rabbits. The TZV metabolite AMTZV [2-methylthio-6-amino-1,2,4-triazolo[5,1-s]-1,2,4-triazin(e)-7(4I)-one] was discovered in IAK 293T and Huh7 cell cultures, a liver homogenate, and rabbit blood after intragastric administration of TZV. AMTZV was nontoxic and inactive as an inhibitor of influenza virus in cell culture. Most likely, this metabolite is a product of TZV elimination.

Topics: Animals; Antiviral Agents; Azoles; Disease Models, Animal; Dogs; Drug Design; Hepatocytes; Humans; Influenza A virus; Influenza B virus; Injections, Intravenous; Kidney; Mice; Mice, Inbred CBA; Orthomyxoviridae Infections; Rabbits; Stomach; Triazines; Triazoles; Virus Replication

2010

[Triazavirin prophylactic efficacy against influenza virus A (H5N1)].

Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2010, Volume: 55, Issue:9-10

The experimental study of the prophylactic efficacy of Triazaverin against the experimental form of the influenza virus A (H5N1) on albino mice intranasally infected with the influenza virus A/Chicken/Kurgan/Russia/02/05 vs. the reference drugs Tamiflu, Remantadin and Arbidol showed that in doses of 1 to 100 mg/kg it was efficient in the animal protection from death. The drug was also efficient in the urgent prophylaxis. Triazaverin effectively inhibited the influenza A virus multiplication in the lungs of the albino mice.

Topics: Administration, Oral; Animals; Antiviral Agents; Azoles; Influenza A Virus, H5N1 Subtype; Lung; Mice; Orthomyxoviridae Infections; Russia; Triazines; Triazoles; Virus Replication

2010